Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Sinn

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
BMC Cancer|October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testRalf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.
Oncoimmunology|October 3, 2024
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinomaIsis Lozzi, Alexander Arnold, Matthias Barone, et al.
Journal of Proteome Research|November 11, 2011
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profilingScarlet F Brockmöller, Elmar Bucher, Berit M Müller, et al.
Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian CancerSofya Marchenko, Niklas Goernitz, Wiebke Alina Zoern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX TrialTheresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 yearsBerit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
BMC Cancer|October 9, 2012
Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis testRalf Kronenwett, Kerstin Bohmann, Judith Prinzler, et al.
Oncoimmunology|October 3, 2024
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinomaIsis Lozzi, Alexander Arnold, Matthias Barone, et al.
Journal of Proteome Research|November 11, 2011
Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profilingScarlet F Brockmöller, Elmar Bucher, Berit M Müller, et al.
Neoplasia (New York, N.Y.)|September 13, 2023
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancerInga Hoffmann, Mihnea P Dragomir, Nanna Monjé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2012
RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapyC Denkert, S Loibl, R Kronenwett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2025
Transcriptome Analysis of Matched Cohorts of Long- and Short-term Survivors in Advanced High-Grade Serous Tubo-ovarian CancerSofya Marchenko, Niklas Goernitz, Wiebke Alina Zoern, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2023
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX TrialTheresa Link, Jens-Uwe Blohmer, Wolfgang D Schmitt, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 yearsBerit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
Human Pathology|September 24, 2023
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinomaSvenja Kolb, Inga Hoffmann, Nanna Monjé, et al.
Pageof 6